Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Diazepam
Drug ID BADD_D00648
Description A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome. (From Martindale, The Extra Pharmacopoeia, 30th ed, p589) Given diazepam's storied history as a commonly used and effective medication for a variety of indications, contemporary advancements in the formulation and administration of the agent include the development and US FDA approval of an auto-injectable formulation for the rapid treatment of uncontrolled seizures in 2015-2016 [L5200]. Combining diazepam, a proven effective therapy for acute repetitive seizures, with an auto-injector designed for subcutaneous administration that is quickly and easily administered offers the potential for complete, consistent drug absorption and rapid onset of effect [L5200]. This current development is subsequently an important addition to the rescue therapy tool chest for patients with epilepsy [L5200].
Indications and Usage In general, diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension, excitation, agitation, fear, or aggressiveness such as may occur in psychoneurosis, anxiety reactions due to stress conditions, and anxiety states with somatic expression.[F3160] Moreover, in acute alcoholic withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, and impending acute delirium tremens.[F3160] Furthermore, diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies, such as inflammation of the muscle and joints or secondary to trauma; spasticity caused by upper motor neuron disorders, such as cerebral palsy and paraplegia; athetosis and the rare "stiff man syndrome".[F3160] Particular label information from the United Kingdom also lists particular age-specific indications, including for adults: (1) The short-term relief (2-4 weeks) only, of anxiety which is severe, disabling, or subjecting the individual to unacceptable distress, occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness, (2) cerebral palsy, (3) muscle spasm, (4) as an adjunct to certain types of epilepsy (eg. myoclonus), (5) symptomatic treatment of acute alcohol withdrawal, (6) as oral premedication for the nervous dental patient, and (7) for premedication before surgery.[L5188] In the same UK label information, diazepam is indicated in children for: (1) control of tension and irritability in cerebral spasticity in selected cases, (2) as an adjunct to the control of muscle spasm in tetanus, and for (3) oral premedication.[L5188] A diazepam nasal spray is indicated in patients 6 years and older to treat intermittent, stereotypic episodes of frequent seizure activity that are different than the patient's usual seizure pattern.[L11247]
Marketing Status approved; illicit; investigational; vet_approved
ATC Code N05BA01
DrugBank ID DB00829
KEGG ID D00293
MeSH ID D003975
PubChem ID 3016
TTD Drug ID D07JVL
NDC Product Code 11014-0400; 43353-825; 45865-482; 49999-018; 58118-3926; 0404-9849; 68682-652; 68788-9207; 71610-460; 72252-510; 76420-533; 80425-0120; 11014-0401; 12828-0013; 38779-0925; 51927-1014; 43353-281; 45865-423; 50090-1913; 55289-092; 63187-544; 0404-9848; 68094-750; 68682-655; 71610-427; 72189-400; 72252-520; 0140-0006; 43063-718; 43353-276; 43353-278; 0172-3927; 45865-140; 63629-1523; 63629-7328; 0378-0271; 0378-0345; 66490-650; 68071-4922; 68788-8281; 69339-136; 70518-2358; 0615-7799; 72189-193; 58118-0640; 67296-0084; 68682-650; 0054-3188; 71610-270; 71610-424; 0641-6243; 80425-0151; 80725-005; 64330-010; 43063-840; 0172-3926; 0187-0659; 51079-286; 58118-3925; 63187-846; 68071-2826; 68788-8466; 69339-137; 76045-204; 43063-970; 51862-942; 58118-4047; 61919-906; 63739-073; 0378-0477; 67544-019; 67544-020; 71335-2196; 72189-401; 80725-006; 51927-0051; 35356-812; 43063-987; 50090-1726; 51079-285; 51862-943; 55154-5074; 55154-5554; 61919-409; 67296-0291; 68071-4770; 68788-8462; 70518-1713; 71872-7259; 72252-515; 72572-140; 11014-0399; 11704-600; 0140-0004; 0187-0658; 60687-755; 63629-2948; 0409-1273; 0527-1768; 71335-0444; 72252-505; 80725-004; 48087-0005; 48087-0112; 0172-3925; 51079-284; 51862-941; 63187-173; 63187-867; 68071-2828; 70518-0014; 71335-2197; 71335-2198; 71610-459; 0615-7800; 0904-7117; 51552-1025; 0140-0005; 52584-213; 53002-3340; 55700-058; 68071-3406; 0409-3213; 68788-7452; 70518-0162; 71335-1584; 71872-7260; 0641-6244; 71554-118; 0121-0905
UNII Q3JTX2Q7TU
Synonyms Diazepam | 7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one | Diazemuls | Faustan | Valium | Seduxen | Sibazon | Stesolid | Apaurin | Relanium
Chemical Information
Molecular Formula C16H13ClN2O
CAS Registry Number 439-14-5
SMILES CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood disorder01.05.01.004--Not Available
Disease recurrence08.01.03.050--Not Available
Obstructive airways disorder22.03.01.0110.000186%Not Available
Psychotic disorder19.03.01.0020.000478%
Pulmonary function test decreased13.19.01.001--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Sensorimotor disorder17.05.03.0090.000050%Not Available
Metabolic encephalopathy17.13.01.001; 14.11.01.0130.000050%Not Available
Electrocardiogram low voltage13.14.05.021--Not Available
Increased bronchial secretion22.12.01.002--Not Available
Arterial occlusive disease24.04.02.0210.000050%Not Available
Brain stem syndrome17.02.10.0160.000050%Not Available
Pyramidal tract syndrome17.05.05.0030.000126%
Gastrointestinal inflammation07.08.03.0070.000050%Not Available
Cardiovascular insufficiency24.06.03.005; 02.11.01.011--Not Available
Substance abuse19.07.06.0180.000604%Not Available
Mixed liver injury09.01.07.0150.000050%Not Available
Liver injury12.01.17.012; 09.01.07.022--Not Available
Psychiatric decompensation19.01.02.0100.000076%Not Available
Low birth weight baby18.04.02.0030.000227%Not Available
Gastrointestinal sounds abnormal07.01.01.0020.000050%Not Available
Intellectual disability19.21.06.001; 17.03.07.0010.000050%Not Available
Hypertransaminasaemia09.01.02.0050.000076%Not Available
Anorectal discomfort07.03.03.003--Not Available
Acute kidney injury20.01.03.0160.001007%
Hypoxic-ischaemic encephalopathy22.02.02.011; 17.13.02.006; 24.04.06.0210.000201%Not Available
Slow speech19.19.02.004; 17.02.08.0160.000076%Not Available
Drug-induced liver injury09.01.07.023; 12.03.01.044--Not Available
Substance-induced psychotic disorder19.03.01.007; 12.03.01.0530.000151%Not Available
Drug reaction with eosinophilia and systemic symptoms23.03.05.005; 10.01.01.021; 12.03.01.0640.000504%Not Available
The 16th Page    First    Pre   16 17 18    Next   Last    Total 18 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene